Brian Skorney

James Condulis

Kristen Kluska

Leland Gershell

Yale Jen

Yasmeen Rahimi

Debjit Chattopadhyay

Myriam Belghiti

Rye Forseth

Tyler Van Buren

Ry Forseth

- On **August 15, 2025**, Soleno Therapeutics, Inc. (SLNO) shares experienced a significant drop after **Scorpion Capital** published a highly critical report.  **[1484565_6dde74f47e71484ca50dc790609c2418_0]** 
- **Hagens Berman**, a national shareholders rights firm, has opened an investigation into Soleno, probing whether the company misled investors about the safety and commercial prospects of its drug, **VYKAT™ XR**.  **[1484565_6dde74f47e71484ca50dc790609c2418_0]** 
- Scorpion Capital's report alleged that **VYKAT™ XR** could be at risk of market withdrawal or plunging new prescriptions due to reports of children hospitalized for potential heart failure, described Soleno as a "**one-trick pony**" with its core patent set to expire in **2026**, and raised concerns about "hocus-pocus" launch metrics and data integrity issues related to a "controversial physician".  **[1484565_6dde74f47e71484ca50dc790609c2418_0]**

Soleno Therapeutics Faces Investigation Following Critical Report

SOLENO THERAPEUTICS (SLNO)